Reimbursement conditions for Pertuzumab

According to the relevant regulations of the domestic medical insurance bureau, the reimbursement scope of Pertuzumab (Pertuzumab) includes neoadjuvant treatment for patients with HER2-positive locally advanced, inflammatory or early breast cancer and adjuvant treatment for patients with HER2-positive early breast cancer with a high risk of recurrence, and medical insurance payment will not exceed 12 months. The reimbursement ratio is different in different regions, and the price after reimbursement will also vary.

As aHER dimerization inhibitor, pertuzumabhas promise for broad application in a variety of tumor types, especially since it is hypothesized thatHER2/neu overexpression is not required for it to be active. Pertuzumab has proven to be a promising agent in metastatic HER2-positive breast cancer, with its combination with trastuzumab showing impressive activity in women who had progressed on trastuzumab-based therapy. The antibody has also shown excellent efficacy in combination with trastuzumab and chemotherapy in the neoadjuvant setting, and the single-agent activity of pertuzumab without any chemotherapy backbone has proven to be very limited, even in HER2-positive breast cancer

Pertuzumab is a strictly controlled drug, and the price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to the exchange rate). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.